Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 18th Annual Pharma Middle East Congress Radisson Blu Hotel, Yas Island, Abu Dhabi, UAE.

Day 1 :

  • Drug Discovery and Novel Drug Delivery Systems
Location: Abu Dhabi

Session Introduction

Soumen Pattanayek

Teva Pharmaceuticals, USA

Title: Osmotic Drug Delivery System: An overview
Speaker
Biography:

Soumen Pattanayek is currently a Sr. Research Fellow, Research & Development at Teva Pharmaceuticals, Weston, FL, USA (Formerly Actavis Laboratories FL, Inc.). He is responsible for product development and scale up of oral sustained and controlled release formulations. Soumen Pattanayek is working with Teva Pharmaceuticals, Weston, FL, USA for 10 years. He has developed multiple products through different platform technologies. Soumen has expertise in various technologies like Osmotic (bi-layer push pull system & monolithic system), MUPS (multi-unit pellet system), Matrix system, delayed release, coating controlled drug delivery system, compressed coated, bi-layer, wurster coating etc. Soumen has proven track record for working on novel drug delivery system. Soumen also has experience working on NCE. Previously Soumen was Research Scientist at Corepharma LLC, and has also served as group leader, Sun Pharma Advanced Research Center (SPARC), India. Soumen has over 15 years of experience in development and commercialization in the pharmaceutical industries.

Abstract:

Osmotic systems are the most reliable controlled drug delivery systems (CDDS) and can be employed as oral drug delivery systems. Osmotic pressure is used as the driving force for these systems to release the drug in a controlled manner. Osmotic pump tablet (OPT) generally consists of a core including the drug(s), an osmotic agent, other excipients and semipermeable membrane coat. Osmosis is an aristocratic phenomenon that seizes the attention for its exploitation in zero-order drug delivery systems. It acts as the driven force for release of drug from the dosage form. The osmotic tablet worked on the principle Osmosis i.e. movement of water across a selectively permeable membrane driven by a difference in osmotic pressure across the membrane. It is driven by a difference in solute concentration across the membrane that allows passage of water but rejects most solute molecules or ions. On the basis of this principle, osmotic drug delivery gives better drug release, not depends on the concentration of the drug and better results than any other controlled release system. Controlled drug release systems attempt to sustain drug action at a predetermined rate by maintaining a relatively constant, effective drug level in the body with minimization of undesirable side effects. In oral NDDS, the development of the Osmotic drug delivery system is a significant milestone for an innovative and highly versatile drug delivery system.

Speaker
Biography:

Alap Choudhari is working in the pharmaceutical industry as a research scientist for more than 15 years. His primary area of research work is focused on the development of solid oral, liquids and transdermal formulations. In his current assignment, he is responsible to develop difficult to develop and complex generic formulations. Dr Choudhari and his team has developed the generic formulation for 6-8 abuse-deterrent formulations and filled them with regulatory agencies. Due to his constant interactions with the regulatory agencies, he has knowledge of most updated requirements which the agencies are trying to enforce to make these formulations more difficult to abuse and safe for the patients. He is also involved in the development of in-house abuse-deterrent formulation platform which is being used for various opioid formulations.  

 

Abstract:

During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic and acute pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescription opioid-related harm is a complex, multifactorial issue that requires a multifaceted solution. To confront the staggering human and economic toll created by opioid abuse and addiction, employing novel technologies are one part of a comprehensive intervention strategy that can deter abuse of prescription opioid analgesics without creating barriers to the safe use of prescription opioids. Abuse-resistant opioids include those that use some kind of physical barrier to prevent tampering with the formulation. Abuse-deterrent opioids are not necessarily resistant to tampering but contain substances that are designed to make the formulation less attractive to abusers. Some significant technological advances are made by researchers and institutions to develop the formulation which can achieve the tamperproof formulation while maintaining the desired pharmacokinetic profile for the opioids. 

Speaker
Biography:

Dr Ibrahim Elsayed is an associate professor and chair of Pharmaceutical Sciences department at Gulf Medical University, Ajman UAE. He did his PhD in Pharmaceutics and Industrial Pharmacy from Cairo University in 2011 and graduation diploma in Health-Professions Education from Gulf Medical University in 2015. He has experience in teaching almost all pharmaceutics courses including dosage forms, biopharmaceutics, pharmacokinetics, reaction kinetics, industrial pharmacy, quality control and assurance. As an administrator, he did preparation of the self-study report for CAA accreditation and ACPE certification, Developing integrated pharmacy curricula., Preparation of the college strategic plan 2017-2022, Participation in employment, quality assurance, assessment and curriculum committees, Developing and monitoring course and instructor online evaluation forms, Preparation and revision of course syllabi and files, Creating lectures and exams timetables using advanced software, Establishing nanotechnology research and IV skills labs.

Abstract:

Lipotomes is novel lipid-based nanocarriers composed of cetyl alcohol and a surfactant such as Tween 80. Lipotomes combine the lipophilic environment of cetyl alcohol and solubilizing effect of Tween 80 and so, it offers a dual action for increasing drug bioavailability. Consequently, lipotomes could be the key tool for the bioavailability enhancement of water-insoluble drugs suffering from a significant inactivation by the first pass effect. Moreover, prolipotomes has been developed to increase its physical stability through out the shelf-life.  Prolipotomes are hydrated after administration to form the lipotomal nanovesicles in situ. On the other hand, lipotomes can enhance transdermal delivery of wide range of drugs due to its nano-size and the presence of Tween 80 that can act as a physical penetration enhancer through disrupting the lipid layers of the skin.

  • Pharmacognosy
Speaker
Biography:

Howaida I. Abd-Alla, Ph.D., specializes in metabolomics natural products chemistry and completed her PhD at the University of Cairo in 2004. After spending time as a postdoctoral fellow at Laboratoire des Interactions Moléculaires et Réactivité Chimique et Photochimique UMR CNRS 5623, Université de Toulouse, France, she became a professor in the Chemistry of Natural Compounds Department, National Research Centre, Egypt. Currently, Prof. Dr Abd-Alla works as the head of the department where her research focuses primarily on isolation, purification and identification of natural compounds from medicinal plants, bacteria and marine organisms using advanced techniques for identification (1D and 2D NMR analysis), synthesis of derivatives of natural products, and bioactive assays in vivo and in vitro in natural products for use in treating different diseases.

Abstract:

Analyzing the lipid and protein content of leaves and roots of Aloe barbadensis collected from Egypt (AEG) and Tunisia (ATUN) was carried out using by GLC and HPLC respectively. The HSV-1 infected chicken embryo fibroblasts cell lines were used for evaluation of the in vitro antiviral effect. A rapid and high frequency shoots multiplication, rooting and acclimatization protocols for elite Aloes using shoot tip explants was developed. Preliminary comparative molecular screening in vitro propagated aloes was carried out and randomly amplified polymorphic DNA (RAPD) markers have been used to check for genetic fidelity of aloes plantlet. Shoot tips explants of the two types were cultured on Murashige and Skoog’s (MS) basal medium supplemented with different plant growth regulators TDZ, BAP, NAA for shoots proliferation and roots formation. After two weeks, in vitro grown plants were transferred to the poly-cups containing 1:1 ratio of soil and sand respectively for hardening and then transferred to garden showed 75% of survival. The DNA fingerprint genetic integrity of the multiplied shoots and acclimatized plantlets were evaluated by employing RAPD marker assays. There was great variability in chemical constituents of AEG and ATUN. All the tested samples showed effective antiviral activity with IC50 range of 5-6 µg/mL and substantial therapeutic indices (TI) range of 80 - 83. Cytotoxicity assay indicated that CC50 of leaves and roots of AEG and ATUN were greater than 400 and 500 mg/mL, respectively. Shoot proliferation was found to be best (80%) using MS medium containing BAP 2.0 mg/L. Moreover, the second subcultures recorded the highest and significant shooters multiplication.  of adventitious root formation was observed in half-strength MS medium supplemented with IBA. Over 95% of rooted plantlets survived acclimatization was remarked. The current results indicated that the geographical localization had a significant impact on the quality of each Aloe.

Speaker
Biography:

Bouheroum Mohammed his research field in phytochemistry doing research on Algerian medicinal plants looking for bioactive molecules. He has a Master Degree from Manchester University and PhD since 2007 from the University of Frères Mentouri of Constantine (Algeria); He is currently Professor and chief of a team doing phytochemistry research on Algerian medicinal plants in VARENBIMOL laboratory at the same University.

Abstract:

The modern pharmaceutical industry relies mainly on the diversity of plant secondary metabolites to find new molecules with novel biological properties; in this perspective, our objectives are the inventory as well as the chemical and pharmacological evaluation of Algerian species, in order to valorize and rationalize their traditional uses and to isolate compounds of potential therapeutic interest. n-butanol and ethyl acetate extracts of Gymnocarpos decander (Caryophyllaceae) were able to isolate five new products including two saponins and three flavonols glycosides, with three known products. The extract obtained undergoes chromatographic and spectroscopic investigations in order to isolate and establish the structures of the molecules that compose them by using various spectroscopic experiments (UV, 1D NMR and 2D and SM).

  • Nanotechnology in Pharma Studies
Speaker
Biography:

Dr Zahid Hussain (PhD) is presently serving as Assistant Professor at Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Selangor, Malaysia. Besides several academic responsibilities, he is holding a position as executive head of quality control department of “Good Manufacturing Practices (GMP) Unit” at Universiti Teknologi MARA, Malaysia. He established numerous research collaborations with prestigious scientists around the globe. He has authored more than 50 peer-reviewed research/review articles in high impact factor, well-ranked international journals and 3 book chapter. He is a recipient of several prestigious honours and awards. He is an editorial board member for 3 international journals and is an official reviewer of more than 30 well-reputed peer-reviewed international journals. His research interests include fabrication, characterization, and formulation of nanotechnology-based topical, percutaneous and transdermal drug delivery systems for the efficient management of skin inflammatory disorders including psoriasis, atopic dermatitis and acute-to-chronic wound.

Abstract:

Atopic dermatitis (AD) is a chronically relapsing eczematous skin disease characterised by frequent episodes of rashes, severe flares, and inflammation. Till date, there is no absolute therapy for treatment of AD; however, topical corticosteroids (TCs) are the majorly prescribed class of drugs for the management of AD. However due to numerous local and systemic adverse effects associated with the use of TCs, topical calcineurin inhibitors (TCIs) have alternatively been well prescribed agents. Though, the topical route is most preferable; however, a limited penetration of therapeutics across the stratum corneum (SC) is one of the major challenges to topical formulations. Owing to excellent biomedical achievements of nanomedicines in the last few decades, nano-delivery systems have gained remarkable recognition for targeted delivery of therapeutic payload, reduced off-target effects, and improved biopharmaceutical profiles of drugs. Therefore, we aimed to fabricate polymeric nanoparticles (NPs) to deliver tacrolimus (TCS) to deeper layers of the skin in order to alleviate its systemic toxicity and improved therapeutic efficacy for treatment of AD. To further optimize the targeting efficiency, TCS-loaded NPs were coated with hyaluronic acid (HA). HA plays multifaceted role in regulating the various biological processes and maintaining homeostasis into the body. Plenteous researches have evidenced the biomedical implications of HA in the skin repair, wound healing, tissue regeneration, anti-inflammatory, and immunomodulation. Following the various physicochemical optimizations, the prepared HA-TCS-CS-NPs were tested for in vitro drug release kinetics, drug permeation across the stratum corneum, percentage of drug retained in the epidermis and dermis, and anti-AD efficacy. Results revealed that HA-TCS-CS-NPs exhibit sustained release profile, promising drug permeation ability, improved skin retention, and pronounced anti-AD efficacy. Conclusively, we anticipated that HA-based modification of TCS-CS-NPs could be a promising therapeutic approach for rationalized management of AD, particularly in children as well as in adults having steroid phobia.

  • Recent Trends in Pharma & Oncology
Speaker
Biography:

Faiza Meftah is the Lead pharmacist for Surgery at Papworth Hospital NHS Foundation Trust in Cambridge (United Kingdom). It is one of the largest cardiothoracic (heart and lung) hospitals in Europe and includes the country's main heart and lung transplant centre. Faiza has received her Master degree in Pharmacy from the University of Nottingham (UK) in 2005 and obtained a Post-Graduate Diploma in Clinical Pharmacy from the University of East Anglia (UK) in 2011. This has enabled her to practice in different specialities within hospital before specializing in Surgery.

Abstract:

Clinical pharmacists, as members of multidisciplinary clinical teams, play a pivotal role within different specialities in UK hospitals and primary care setting. Their role extends from a routine review of prescriptions, medicines information, formulary applications, and drug history-taking through medicines reconciliation, assisting prescribers in prescribing decisions, optimising drug therapy, and therapeutic drug monitoring (TDM), to facilitating patient discharge from hospitals, and counselling patients on their medication prior to discharge.

 

Speaker
Biography:

Hashem Alsaab: Experienced Research scientist with a demonstrated history of working in the higher education and clinical practice. Skilled in Pharmaceutical sciences Cancer research, Drug delivery, nanotechnology, and Biotechnology. Strong research professional with a PhD from Dr Iyer’s group in U-BiND Systems Laboratory, Department of Pharmaceutical Sciences, EACPHS Wayne State University, USA; Doctor of Pharmacy (Pharm.D) and Master of Science (M.S.) focused in Pharmaceutical Sciences- Industrial Pharmacy option from University of Toledo, OH USA. Currently, work as Assistant Professor of Pharmaceutics and Pharmaceutical Technology, Taif University, Saudi Arabia. 

Abstract:

Several cancer immunotherapeutic approaches have been recently introduced into the clinics and they have shown remarkable therapeutic potentials. The groundbreaking cancer immunotherapeutic agents function as a stimulant or modulator of the body immune system to fight against or treat cancers. Although targeted immunotherapies such as immune checkpoint inhibitors (CTLA-4 or PD-1/PD-L1), DNA vaccination and CAR-T therapy are revolutionizing cancer treatment, the delivery efficacy can be further improved while their off-target toxicity can be mitigated through nanotechnology approaches. Nanomedicines can be multifunctional drug delivery agents for cancer therapies. However, they have faced several challenges in clinical trials owing to poor targeting ability, insufficient tumour penetration, difficulty in the synthesis and scale up, and limited understanding of interactions between a tumour and nanoparticles. In this regard, tumour multicomponent targeting drug delivery systems are a rational approach to developing tumour-site-specific therapeutics. The nanoparticles can be co-loaded with drugs, genes and imaging agents, surface decorated with varying targeting ligands that can home to varying tumours and/or a tumour multicomponent. Recent research has demonstrated that nanotechnology has multifaceted role for (i) reeducating tumour-associated macrophages (TAM) to function as tumour suppressor agent, (ii) serving as an efficient alternative for Chimeric Antigen Receptor (CAR)-T cell generation and transduction, and (iii) selective knockdown of Kras oncogene addiction by nano-Crisper-Cas9 delivery system. The function of host immune stimulatory signals and tumour immunotherapies can further be improved by repurposing of nanomedicine platform. This presentation will summarize the role of multifunctional polymeric, lipid, metallic and cell-based nanoparticles for improving current immunotherapy